As part of our Virtual Life Fest celebration, we hosted a Virtual GIST Do It Walk on Sunday, July 12, 2020. The walk was held in memory of Ted Wolf, who lost his battle with GIST in 2018.
Blueprint Medicines and Deciphera Pharmaceuticals celebrated GIST Awareness Day (GAD), July 13th, 2020, with Virtual Walks across the U.S. This year's GIST Awareness Day theme was #GISTHope.
Partnerships and collaborations are critical to the progress of research in rare diseases. GIST specialist & Pediatric & SDH-Deficient GIST Consortium member, Dr. Jason Sicklick, and LRG member, Debra Melikian, are working together find a cure for succinate dehydrogenase-deficient gastrointestinal stromal tumors (SDH-deficient GIST), a hereditary rare cancer syndrome which claimed the lives of Debra’s husband and her son Merak.
András Szekfü, of Budapest, Hungary, shares his GIST journey in this video for GIST Awareness Day, a day set aside to bring awareness of this disease.
The Life Raft Group has been an integral part of a pan-cancer Working Group designed to determine consistent terminology around biomarker or mutational testing. The goal is to communicate to patients and the larger community in plain, patient friendly and consistent language what these terms mean, and how they impact on precision medicine.
In this webinar, we discussed how to interpret your pathology report. We covered interpretation of all parts of a pathology report, beginning with understanding the final diagnosis and diagnostic comment.
GIST Mentors Santy DiSabatino, Marlene Nei and Rob Taylor will discuss the role of the GIST Mentor and how a Mentor can assist you on your GIST journey.
Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST.
Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of 4L Gastrointestinal Stromal Tumor
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.
La FDA aprobó QINLOCKTM (ripretinib) para el tratamiento de adultos con tumor avanzado del estroma gastrointestinal (GIST) que han recibido 3 o más tratamientos previos para su GIST.